Method and system for growing molluscum contagiosum in xenografts to immunocompromised hosts

• US 5,885,822 A
• Filed: 08/20/1996
• Issued: 03/23/1999
• Est. Priority Date: 08/20/1996
• Status: Expired due to Fees

• Current Assignee: David A. Paslin
• Original Assignee: David A. Paslin
• Inventors: Paslin, David A.
• Primary Examiner(s): Scheiner, Laurie
• Assistant Examiner(s): Parkin, Jeffrey S.
• Application Number:
  US08/699,744
• Time in Patent Office: 945 Days
• Field of Search: 435/1.1, 435/235.1, 435/239, 424/93.1, 424/204.1, 424/232.1
• US Class Current: 435/235.1
• CPC Class Codes: C12N 2710/24051 Methods of production or purification of viral material
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

A method and system is provided for the growth of the molluscum contagiosum virus in human skin xenografted to an immunocompromised host. A human skin graft is infected with molluscum contagiosum virus attached to or beneath a skin section of the immunocompromised host. According to the method, a section of skin of an immunocompromised host is prepared for receiving a human skin xenograft which is then placed onto or into the host. The human skin is infected with the molluscum contagiosum virus. The animals are monitored and the newly grown virus and its products are harvested for further study.

Claims

1. A method for growing molluscum contaglosum virus (MCV) in human keratinocytes comprising:

preparing a xenograft of human epithelial tissue;

grafting the xenograft onto or into an immunocompromised host;

infecting the xenograft with MCV either before or after grafting the xenograft onto or into the immunocompromised host;

wherein the infection results in productive MCV replication and the production of progeny virus.

3. The method according to claim 1 wherein

the step of preparing a xenograft of human epithelial tissue includes

exposing a sufficient area of a capillary bed surface of the immunocompromised host to support the xenograft;

and

the step of grafting the xenograft onto or into an immunocompromised host includes grafting the xenograft to the host such that a dermal side of the xenograft is in contact with the exposed area of the capillary bed surface.

4. The method according to claim 1 wherein the human epithelial tissue is postnatal skin.

5. The method according to claim 4 wherein the human epithelial tissue is a foreskin.

6. The method according to claim 1 wherein the human epithelial tissue is selected from the group consisting of glabrous skin, hair bearing skin and mucous membrane.

7. The method according to claim 1 wherein the host is an immunodeficient host.

8. The method according to claim 3, the step of exposing an area of a capillary bed surface including removing a section of skin from the immunocompromised host such that an area of a capillary bed surface on the immunocompromised host is exposed.

9. The method according to claim 3,

the step of exposing an area of a capillary bed surface including uplifting a section of skin from a body of the immunocompromised host, and

the step of grafting the xenograft including grafting the xenograft to the area of the capillary bed in a cutaneous site, a subcutaneous site within the body, or on the uplifted section of skin and grafting the uplifted skin section to the body of the host.

10. The method according to claim 8, wherein the step of uplifting the host skin section is performed such that the exposed capillary bed surface is positioned on the host body.

11. The method according to claim 10, wherein the step of grafting the xenograft includes grafting the xenograft to the host body.

12. The method according to claim 10, wherein the step of grafting the xenograft includes grafting the xenograft to the uplifted host skin section.

13. The method according to claim 9, wherein the step of uplifting the host skin section is performed such that the exposed capillary bed surface is positioned on the uplifted host skin section.

14. The method according to claim 13, wherein the step of grafting the xenograft includes grafting the xenograft to the host body.

15. The method according to claim 13, wherein the step of grafting the xenograft includes grafting the xenograft to the uplifted host skin section.

22. The method according to claim 7 wherein the immunodeficient host is selected from the group consisting of SCID mice, NOD-SCID mice, nude mice, N-III nude mice and nude rats.

2. A system for expressing molluscum contaglosum virus (MCV) comprising:

a xenograft of human epithelial tissue infected with MCV grafted onto or into an immunocompromised host such that the infection results in productive MCV replication and the production of progeny virus.

16. The expression system according to claim 2 wherein the xenograft of human epithelial tissue grafted onto or into an immunocompromised host is a xenograft in contact with an area of a capillary bed surface of the immunocompromised host.

17. The expression system according to claim 2 wherein the xenograft is postnatal skin or mucous membrane.

18. The expression system according to claim 2 wherein the immunocompromised host is a mammal whose immune system is genetically impaired.

19. The expression system according to claim 2 wherein the immunocompromised host is selected from the group consisting of SCID mice, NOD-SCID mice, nude mice, N-III nude mice and nude rats.

20. The expression system according to claim 16 wherein a host skin section is removed to expose a sufficient area of the capillary bed surface to support a tissue graft and the xenograft is attached to the area of the capillary bed surface at the location where the host skin section is removed.

21. The expression system according to claim 16 wherein a section of skin of the immunocompromised host is uplifted from a body of the immunocompromised host to expose a sufficient area of the capillary bed surface to support a tissue graft, the xenograft is grafted to either the body or the uplifted section of skin.

23. The expression system according to claim 2 wherein complete replicative cycles of MCV occur for at least 2 weeks after infection.